Veterinary Recombinant Biologics

KindredBio is revolutionizing veterinary therapeutic biologics, such as monoclonal antibodies and recombinant proteins.

Next Generation Therapeutics: Biologics

In humans, therapeutic biologics have revolutionized medicine, providing safe and effective treatments for many diseases, including various cancers and autoimmune disorders. KindredBio is developing next-generation veterinary therapeutic biologics — such as monoclonal antibodies and recombinant proteins — for dogs and cats.

Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by identical cells that are cloned from a unique parent cell. They bind to a specific epitope on the targeted cell type or soluble target.

Monoclonal antibodies are deemed by many to be the gold standard of treatment for many diseases because of their safety and efficacy profile as well as their high specificity and long half-life.

Examples of this technology in human medicine include:

Usage in infliximab (Remicade^®) and Adalimumab (Humira^®), which help treat Crohn’s disease, ulcerative colitis, and rheumnatoid arthritis as anti-inflammatory monoclonal antibodies that inhibit TNFa.^1,2
Rituximab (Rituxan^®), a monoclonal antibody to CD20 on B cells, can treat non-Hodgkin’s lymphomas.³
Monoclonal antibodies also can be used against inflammatory and autoimmune disorders as well as cancer. For example, Bevacizumab (Avastin^®) and Ranibizumab (Lucentis^®) are approved for use in humans. ^4,5

Recombinant Proteins

Recombinant biologics are produced by inserting the genetic code for a specific therapeutic protein into the DNA of an expression vector in the laboratory. The inserted DNA codes result in large quantities of recombinant protein produced through replication in living host cells.

Then we purify the recombinant protein and administer it to the animal (cat, dog, or horse) for targeted therapy. This final preparation (drug formulation) is sterile and contains a highly pure and targeted drug. One recombinant protein commonly used in human medicine is erythropoietin alpha (Epogen®).⁶

The Process of Creating Recombinant Proteins

Step 1: Identify

Identify and isolate the genetic code for the desired therapeutic protein.

Step 2: Insert

Insert the code into the expression vector.

Step 3: Produce

The host cell produces a recombinant protein.

Step 4: Collect

Collect, separate, and purify recombinant proteins from the host cell proteins.

Step 5: Formulate

The final drug formulation is sterile and contains a highly pure drug substance capable of binding to the specific epitope on the cell receptor or to a soluble target (such as cytokine).

Learn More

Watch this video to learn more about how KindredBio is a pioneer in the field of veterinary therapeutic recombinant protein technology.

REMICADE® (infliximab) Lyophilized Concentrate for Injection, for Intravenous Use [Full Prescribing Information], Janssen Biotech, Inc. (Horsham, PA). Revised: 10/2017.
HUMIRA® (adalimumab) Injection, for Subcutaneous Use [Full Prescribing Information], AbbVie Inc. (North Chicago, IL). Revised: 12/2017.
RITUXAN® (rituximab) Injection, for Intravenous Use [Full Prescribing Information], Genentech, Inc. (South SanFrancisco, CA). Revised: 12/2017.
AVASTIN® (bevacizumab) Injection, for Intravenous Use [Full Prescribing Information], Genentech, Inc. (South San Francisco, CA). Revised: 12/2017.
LUCENTIS® (ranibizumab) Injection, for Intravitreal Injection [Full Prescribing Information], Genentech, Inc. (South San Francisco, CA). Revised: Revised: 4/2017.
EPOGEN® (epoetin alfa) injection, for intravenous or subcutaneous use [Full Prescribing Information], Amgen Inc. (Thousand Oaks, CA). Revised: 05/2012.

US-CORP-2000010 FEB-20